Skip to main content
. 2021 Jul 22;11:15007. doi: 10.1038/s41598-021-94572-z

Figure 5.

Figure 5

IL-17A plays important role to enhance antibacterial activity of combination therapy with C. butyricum against C. difficile and activate plasma B cell to enhance IgA production. (A) Interleukin (IL)-6, Transforming growth factor-β1 (TGF-β1) and (B) IL-17A protein expressions in mice colon lumina propria (cLP) detected at day 8. All values are mean ± SD (n = 5–10). (C) The relative RNA expression of genes encoding proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF) in colon tissues of mice, detected by qPCR. All values are mean ± SD (n = 5–10). (D) Representative flow cytometry plots of B cell (CD45R/B220+/CD19+/CD138-) and plasma B cell (CD45R/B220+/CD19/CD138+) expressions among leukocytes in the colonic lamina propria (cLP) in the fidaxomicin monotherapy group (Fidaxo), and combination group (Combination). Percentage of plasma B cell among leukocytes in cLP (right). (E) Representative flow cytometry plots of IL-17A producing CD4+ cell (CD3+/CD4+/IL-17A+) expression among T cells in the cLP in the fidaxomicin monotherapy group (Fidaxo), and combination group (Combination). Percentage of IL-17A producing CD4+ cells among CD4+ cells among T cells in cLP (right).